“… the open market value, at the specified date, of the business and assets of IMS as between a willing buyer and a willing seller contracting at arm’s length, determined on the presumption that the business is a going concern. Such presumption shall only be rebuttable in the event that there is persuasive evidence that a sale of the business as a going concern at the specified date was not commercially viable. The open market value used shall be computed without the application of any discount pertaining to, or arising from, the fact that the business might be encumbered with any liability to [Dr Beynon].”
“…except that he must (a) generally act in good faith to [Dr Beynon].”
“Otherwise [Dr Persaud] shall have complete freedom to manage and direct IMS in such ways as he shall in his absolute discretion see fit, and he shall not be obliged by anything in this agreement to seek to maximise Turnover, Market value, Net Proceeds or the profit of IMS.”
“(5) The highest open market value of IMS is the highest value of the business and assets on the following basis (‘the valuation basis’). (b) The value as between a willing buyer and a willing seller at arm’s length, determined on the presumption that the business was a going concern, such presumption to be rebuttal in the event that there is persuasive evidence that a sale of the business as a going concern was not commercially viable; the highest open market value shall be computed without the application of any discount arising from any liability to … [Dr Beynon].” (b) The value as between a willing buyer and a willing seller at arm’s length, determined on the presumption that the business was a going concern, such presumption to be rebuttal in the event that there is persuasive evidence that a sale of the business as a going concern was not commercially viable; the highest open market value shall be computed without the application of any discount arising from any liability to … [Dr Beynon].”
“In accordance with paragraph 1(d) of the directions of 15 September on the basis that Dr Beynon would have exercised his option under clause 4 of the agreement at the time between1 July 2004 and30 November 2005 when IMS reached its highest open market value, and so Dr Beynon would have been entitled to final commission of 8 per cent of that open market value, and the sale of IMS did not determine that issue.”
“2.1 Mr Eales [Dr Persaud’s expert] and Mr Kerr [Dr Beynon’s expert] agree that the multiplier/multiplicand method of valuation is the appropriate method for valuing the IMS Companies. They also agree that this method involves making adjustments to reported profits in respect of exceptional and/or non-recurring costs and revenues. 2.2 It is acknowledged that this method also requires the net asset position of the business to be addressed in finalising the valuation.”
“It is also necessary in finalising the valuation to look at the balance sheet position of the business, for example, where there is cash at bank well in excess of its working capital requirement, this would need to be reflected in the valuation. Conversely, if the balance sheet position showed net liabilities this would need to be investigated and the results reflected in the valuation.”
“Mr Eales is of the opinion that in the event of any deficit on net assets, such deficit should be subtracted from the value derived on a capitalised earnings basis (ie the multiplier applied to the multiplicand). Mr Kerr understands the principle which Mr Eales is seeking to apply. However, as will be seen in Mr Kerr’s separate report he does not accept that all of these adjustments should be seen as having balance sheet effect.”
“…if, as suggested by Mr Eales, there is a deficit on net assets, such a deficit arises, in my opinion, entirely as a result of [Dr Persaud’s] policy of extracting surplus cash from the IMS Companies for personal expenditure, the funding of this litigation, costs associated with the abortive sale of [IMS] and payments relating to the purchase of shares issued to Ms Middleton and Ms Saltwell. And, as a result, I consider that in this case it would be inappropriate to make an adjustment of the nature suggested by Mr Eales.”
“37. Mr Kerr and Mr Eales also disagreed on which accounts and figures to use in the valuation process, on the multiplier and on the effect on the valuation of a net deficiency in assets. 38. Their final calculations of the value of the IMS business was a follows: (a) Mr Kerr: Using his 2003 final adjusted PBT of£1.37 million and a multiplier of between 6 and 8, his valuation was between£8.2 million and£11 million with no deduction for any deficiency of assets. (b) Mr Eales: Using his 2004 final adjusted PBT of£779,000 and a multiplier of 5 or 6, his capitalised earnings total was between£3.895 million and£4.674 million from which he deducted a net deficiency of assets to produce a final value of£1.035 million to£2.424 million .”
“In August 2003, Dr Persaud made his admission of liability and after I gave directions on15 September 2003 , the valuation process started. Starting in October 2003, Dr Persaud started to approve the massive payments apparently for Ms Saltwell and Ms Middleton and these continued until early 2004. The total paid apparently to Ms Saltwell and Ms Middleton in the 6 months from January to July 2004 was about£1.6 million .” (6) At paragraphs 84 to 94 the arbitrator considered in detail Dr Persaud’s conduct, and concluded at paragraph 95: “I conclude that Dr Beynon has established that the substantial sums which were paid out of IMS and which have resulted in the net asset deficiency calculated by Mr Eales is the result of Dr Persaud acting in breach of his duty of good faith to Dr Beynon.”
“I have considered whether it would be fair to find that Dr Persaud has acted towards Dr Beynon without good faith as Dr Persaud has not given evidence and has not had the opportunity to defend himself or answer cross examination. In the circumstances I am sure that it is fair.”
“(1) A party to arbitral proceedings may, upon notice to the other parties and to the tribunal, apply to the Court challenging an award in the proceedings on the ground of the serious irregularity affecting the tribunal, the proceedings or the award.”